Ignite Creation Date:
2025-12-24 @ 11:33 PM
Ignite Modification Date:
2026-05-30 @ 5:45 AM
Study NCT ID:
NCT04564456
Status:
COMPLETED
Last Update Posted:
2021-01-20
First Post:
2020-09-22
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Pivotal Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers
Sponsor:
Respirent Pharmaceuticals Co Ltd.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
BREATH-BE500-PIVOTAL
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |